Granzyme B producing B-cells in renal transplant patients

Abstract Objectives A separate subset of Granzyme B (GrB) producing B-cells regulating T-cell mediated immunity has been identified. In the present study, we investigated the role of GrB+ B-cells in renal transplant patients (RTX). Methods 12 healthy controls (HC) and 26 RTX patients were enrolled....

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Fla.), 2017-11, Vol.184, p.48-53
Main Authors: Zhu, Jiqiao, Zeng, Ye, Dolff, Sebastian, Bienholz, Anja, Lindemann, Monika, Brinkhoff, Alexandra, Schedlowski, Manfred, Xu, Shilei, Sun, Ming, Guberina, Hana, Kirchhof, Julia, Kribben, Andreas, Witzke, Oliver, Wilde, Benjamin
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Aged
Allergy and Immunology
Allograft rejection
B-cells
B-Lymphocytes - drug effects
B-Lymphocytes - metabolism
Case-Control Studies
Cyclosporine - pharmacology
Cyclosporine - therapeutic use
Female
Graft Rejection - prevention & control
Granzymes - drug effects
Granzymes - metabolism
Humans
Immune tolerance
Immunosuppressive Agents - pharmacology
Immunosuppressive Agents - therapeutic use
Interleukins - pharmacology
Kidney Transplantation
Male
Middle Aged
Mycophenolic Acid - therapeutic use
Regulatory B-cells
Renal transplantation
Tacrolimus - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives A separate subset of Granzyme B (GrB) producing B-cells regulating T-cell mediated immunity has been identified. In the present study, we investigated the role of GrB+ B-cells in renal transplant patients (RTX). Methods 12 healthy controls (HC) and 26 RTX patients were enrolled. In addition, 19 healthy volunteers treated with cyclosporine A (CsA) were enrolled. GrB+ B-cells were determined via flow cytometry. Results RTX Patients showed a diminished fraction of GrB+ B-cells as compared to HC. CsA treatment of healthy volunteers had no impact on the development of GrB+ B-cells. RTX patients with a history of allograft rejection showed an increased frequency of GrB+ B-cells. RTX patients with at least one episode of CMV viremia tended to have lower GrB+ B-cells as compared to patients without viremic episodes. Conclusion We demonstrate that treatment with CsA does not impair the development of GrB+ B-cells. GrB+ B-cells may have a dual role in renal transplantation as regulatory cells to maintain allospecific tolerance and as effector cells enhancing viral control.
ISSN:1521-6616
1521-7035
DOI:10.1016/j.clim.2017.04.016